Relationship between retention index in dual-phase 18F-FDG PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer

Journal of Nuclear Medicine

Volumn 43, Issue 2, 2002, Pages 173-180

  Higashi, Tatsuya ^a   Saga, Tsuneo ^a   Nakamoto, Yuji ^a   Ishimori, Takayoshi ^a   Mamede, Marcelo H ^a   Wada, Michihiko ^a   Doi, Ryuichiro ^a   Hosotani, Ryo ^a   Imamura, Masayuki ^a   Konishi, Junji ^a  

^a KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

18F FDG PET; Glucose transporter; Hexokinase; Pancreatic cancer

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GLUCOSE TRANSPORTER 1; HEXOKINASE;

ADULT; AGED; ARTICLE; BENIGN TUMOR; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE PERIOD; PRIORITY JOURNAL; SCORING SYSTEM; TUMOR DIFFERENTIATION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CYSTADENOCARCINOMA, MUCINOUS; FEMALE; FLUORODEOXYGLUCOSE F18; GLUCOSE TRANSPORTER TYPE 1; HEXOKINASE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MONOSACCHARIDE TRANSPORT PROTEINS; PANCREATIC NEOPLASMS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0036171903     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Recurrence of colorectal tumors: PET evaluation
2. The applications of PET in clinical oncology
3. 18F]-fluoro-2-deoxy-D-glucose
4. PET cancer evaluations with FDG
5. 18F]fluoro-2-deoxy-D-glucose
6. Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: Comparison with CT and US
7. Positron emission tomography with F-18-fluorodeoxyglucose to evaluate the results of hepatic chemoembolization
8. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: Correlation with tumor response to fluorouracil
9. Lymph node staging in non-small-cell lung cancer with FDG PET scan: A prospective study on 690 lymph node stations from 68 patients
10. Positron emission tomography for staging of oesophageal and gastroesophageal malignancy
11. Noninvasive grading of musculosketetal tumors using PET
12. 18FDG uptake in soft tissue masses
13. Optimal scan time for fluorine-18 fluorodeoxy-glucose positron emission tomography in breast cancer
14. Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: A potential method to differentiate malignancy from inflammation and normal tissue in the head and neck
15. Delayed FDG PET scan for differentiation between malignant and benign lesions in the pancreas
16. Hexokinase binding to mitochondria: A basis for proliferative energy metabolism
17. Maximum activities of key enzymes of glycolysis, glutaminolysis, pentose phosphate pathway and tricarboxylic acid cycle in normal, neoplastic and suppressed cells
18. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia
19. Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study
20. Relation of left ventricular perfusion and wall motion with metabolic activity in persistent defects on thallium-201 tomography in healed myocardial infarction
21. GLUTI expression in human breast carcinoma: Correlation with known prognostic markers
22. Functional organization of mammalian hexokinases: Both N-and C-terminal halves of the rat type II isozyme possess catalytic sites
23. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation
24. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG PET
25. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: Variations with body weight and a method for correction
26. Fluorine-18 deoxyglucose and false-positive results: A major problem in the diagnostics of oncological patients
27. Focal fluorine-18 fluorodeoxyglucose accumulation in inflammatory pancreatic disease
28. False-positive FDG PET in patients with pancreatic masses: An issue of proper patient selection [letter]?
29. Untreated primary lung and breast cancers: Correlation between F-18 FDG kinetic rate constants and findings of in vitro studies
30. Dynamic positron emission tomography with F-18 fluorodeoxyglucose imaging in differentiation of benign from malignant lung/mediastinal lesions
31. FDG uptake, tumour characteristics and response to therapy: A review
32. FDG accumulation and tumor biology
33. The importance of glucose transport activity as the rate-limiting step of 2-deoxyglucose uptake in tumor cells in vitro
34. Glut-1 and hexokinase expression: Relationship with 2-fluoro-2-deoxy-D-glucose uptake in A431 and T47D cells in culture
35. Facilitative glucose transporter expression in human cancer tissue
36. FDG uptake, GLUT-glucose transporter and cellularity in human pancreatic tumors
37. Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET
38. The membrane-bound hexokinase as a potential marker for malignancy in human glioma